Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors

Fig. 5

Effects of CUDC-907 on IGR-NB8 cells: NET and DAT mRNA expression and protein levels. A NET mRNA expression levels in IGR-NB8 cells incubated with CUDC-907 0.1 µM and BGT226 0.05 µM. The qPCR was performed on duplicate from three independent experiments. Gene expression was detected between 14.9 and 22.6 Ct. B Representative immunofluorescence images of NET and DAT protein expression in IGR-NB8 cells incubated with CUDC-907 0.1 µM and CUDC-907 0.1 µM along with siRNA, left panels: positive controls: HEK cells transfected with NET- and DAT-encoding plasmids, scale bars correspond to 50 µM. C Quantification of immunofluorescence signal performed in triplicate (three individual fields) for each conditions from at least three independent experiments with the ImageJ software. The ratio corresponds to the NET and DAT signal divided by the signal of the nucleus stain (DAPI) Statistical analysis was performed through the unpaired t-test between the control (DMSO) and CUDC-907 treated cells. *p < 0.05; **p < 0.01

Back to article page